



Urological Medications Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2026-01-01	130	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Urological Medications market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Urological Medications market is projected to increase from US\$ million in 2026 to US\$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Urological Medications market is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

Asia Pacific: the Urological Medications market is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Urological Medications include Abbott, Novartis, Merck, Lilly, Pfizer, GlaxoSmithKline, AbbVie, Viatris and Sanofi-aventis U.S. LLC, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Urological Medications market in terms of revenue (US\$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US\$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Urological Medications.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Urological Medications Market by Company

Abbott

Novartis

Merck

Lilly

Pfizer

GlaxoSmithKline

AbbVie

Viartis

Sanofi-aventis U.S. LLC

Piramal Pharma Solutions

Mallinckrodt

Endo International

Bayer HealthCare Pharmaceuticals

Astellas Pharma

ADVANZ PHARMA

Urological Medications Segment by Type

Anticholinergics

Alpha Blockers

5-Alpha Inhibitors

Others

Urological Medications Segment by Application

OAB

ED

Prostate Cancer

BPH

SUI

Others

Urological Medications Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urological Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Urological Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urological Medications.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4:

Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5:

Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6:

Detailed analysis of Urological Medications companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Urological Medications by Type
 - 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
 - 2.2.2 Anticholinergics
 - 2.2.3 Alpha Blockers
 - 2.2.4 5-Alpha Inhibitors
 - 2.2.5 Others
- 2.3 Urological Medications by Application
 - 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.3.2 OAB
 - 2.3.3 ED
 - 2.3.4 Prostate Cancer
 - 2.3.5 BPH
 - 2.3.6 SUI
 - 2.3.7 Others
- 2.4 Assumptions and Limitations

3 Urological Medications Breakdown Data by Type

- 3.1 Global Urological Medications Historic Market Size by Type (2021-2026)
- 3.2 Global Urological Medications Forecasted Market Size by Type (2027-2032)

4 Urological Medications Breakdown Data by Application

- 4.1 Global Urological Medications Historic Market Size by Application (2021-2026)
- 4.2 Global Urological Medications Forecasted Market Size by Application (2027-2032)

5 Global Growth Trends

- 5.1 Global Urological Medications Market Perspective (2021-2032)
 - 5.2 Global Urological Medications Growth Trends by Region
 - 5.2.1 Global Urological Medications Market Size by Region: 2021 VS 2025 VS 2032
 - 5.2.2 Urological Medications Historic Market Size by Region (2021-2026)
 - 5.2.3 Urological Medications Forecasted Market Size by Region (2027-2032)
 - 5.3 Urological Medications Market Dynamics
 - 5.3.1 Urological Medications Industry Trends
 - 5.3.2 Urological Medications Market Drivers
 - 5.3.3 Urological Medications Market Challenges
 - 5.3.4 Urological Medications Market Restraints
-

6 Market Competitive Landscape by Players

6.1 Global Top Urological Medications Players by Revenue

6.1.1 Global Top Urological Medications Players by Revenue (2021-2026)

6.1.2 Global Urological Medications Revenue Market Share by Players (2021-2026)

6.2 Global Urological Medications Industry Players Ranking, 2023 VS 2024 VS 2025

6.3 Global Key Players of Urological Medications Head Office and Area Served

6.4 Global Urological Medications Players, Product Type & Application

6.5 Global Urological Medications Manufacturers Established Date

6.6 Global Urological Medications Market CR5 and HHI

6.7 Global Players Mergers & Acquisition

7 North America

7.1 North America Urological Medications Market Size (2021-2032)

7.2 North America Urological Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032

7.3 North America Urological Medications Market Size by Country (2021-2026)

7.4 North America Urological Medications Market Size by Country (2027-2032)

7.5 United States

7.5 United States

7.6 Canada

7.7 Mexico

8 Europe

8.1 Europe Urological Medications Market Size (2021-2032)

8.2 Europe Urological Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032

8.3 Europe Urological Medications Market Size by Country (2021-2026)

8.4 Europe Urological Medications Market Size by Country (2027-2032)

8.5 Germany

8.6 France

8.7 U.K.

8.8 Italy

8.9 Spain

8.10 Russia

8.11 Netherlands

8.12 Nordic Countries

9 Asia-Pacific

9.1 Asia-Pacific Urological Medications Market Size (2021-2032)

9.2 Asia-Pacific Urological Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032

9.3 Asia-Pacific Urological Medications Market Size by Country (2021-2026)

9.4 Asia-Pacific Urological Medications Market Size by Country (2027-2032)

9.5 China

9.6 Japan

9.7 South Korea

9.8 India

9.9 Australia

9.10 China Taiwan

9.11 Southeast Asia

10 South America

10.1 South America Urological Medications Market Size (2021-2032)

10.2 South America Urological Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032

10.3 South America Urological Medications Market Size by Country (2021-2026)

10.4 South America Urological Medications Market Size by Country (2027-2032)

10.5 Brazil

10.6 Argentina

10.7 Chile

10.8 Colombia

10.9 Peru

11 Middle East & Africa

11.1 Middle East & Africa Urological Medications Market Size (2021-2032)

11.2 Middle East & Africa Urological Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032

11.3 Middle East & Africa Urological Medications Market Size by Country (2021-2026)

11.4 Middle East & Africa Urological Medications Market Size by Country (2027-2032)

11.5 Saudi Arabia

11.6 Israel

11.7 United Arab Emirates

11.8 Turkey

11.9 Iran

11.10 Egypt

12 Players Profiled

12.1 Abbott

12.1.1 Abbott Company Information

12.1.2 Abbott Business Overview

12.1.3 Abbott Revenue in Urological Medications Business (2021-2026)

12.1.4 Abbott Urological Medications Product Portfolio

12.1.5 Abbott Recent Developments

12.2 Novartis

12.2.1 Novartis Company Information

12.2.2 Novartis Business Overview

12.2.3 Novartis Revenue in Urological Medications Business (2021-2026)

12.2.4 Novartis Urological Medications Product Portfolio

12.2.5 Novartis Recent Developments

12.3 Merck

12.3.1 Merck Company Information

12.3.2 Merck Business Overview

12.3.3 Merck Revenue in Urological Medications Business (2021-2026)

12.3.4 Merck Urological Medications Product Portfolio

12.3.5 Merck Recent Developments

12.4 Lilly

12.4.1 Lilly Company Information

12.4.2 Lilly Business Overview

12.4.3 Lilly Revenue in Urological Medications Business (2021-2026)

12.4.4 Lilly Urological Medications Product Portfolio

12.4.5 Lilly Recent Developments

12.5 Pfizer

12.5.1 Pfizer Company Information

12.5.2 Pfizer Business Overview

12.5.3 Pfizer Revenue in Urological Medications Business (2021-2026)

12.5.4 Pfizer Urological Medications Product Portfolio

12.5.5 Pfizer Recent Developments

12.6 GlaxoSmithKline

12.6.1 GlaxoSmithKline Company Information

12.6.2 GlaxoSmithKline Business Overview

12.6.3 GlaxoSmithKline Revenue in Urological Medications Business (2021-2026)

12.6.4 GlaxoSmithKline Urological Medications Product Portfolio

12.6.5 GlaxoSmithKline Recent Developments

12.7 AbbVie

12.7.1 AbbVie Company Information

12.7.2 AbbVie Business Overview

12.7.3 AbbVie Revenue in Urological Medications Business (2021-2026)

12.7.4 AbbVie Urological Medications Product Portfolio

12.7.5 AbbVie Recent Developments

12.8 Viatrix

12.8.1 Viatrix Company Information

12.8.2 Viatrix Business Overview

12.8.3 Viatrix Revenue in Urological Medications Business (2021-2026)

12.8.4 Viatrix Urological Medications Product Portfolio

12.8.5 Viatrix Recent Developments

12.9 Sanofi-aventis U.S. LLC

12.9.1 Sanofi-aventis U.S. LLC Company Information

12.9.2 Sanofi-aventis U.S. LLC Business Overview

12.9.3 Sanofi-aventis U.S. LLC Revenue in Urological Medications Business (2021-2026)

12.9.4 Sanofi-aventis U.S. LLC Urological Medications Product Portfolio

12.9.5 Sanofi-aventis U.S. LLC Recent Developments

12.10 Piramal Pharma Solutions

12.10.1 Piramal Pharma Solutions Company Information

12.10.2 Piramal Pharma Solutions Business Overview

12.10.3 Piramal Pharma Solutions Revenue in Urological Medications Business (2021-2026)

12.10.4 Piramal Pharma Solutions Urological Medications Product Portfolio

12.10.5 Piramal Pharma Solutions Recent Developments

12.11 Mallinckrodt

12.11.1 Mallinckrodt Company Information

12.11.2 Mallinckrodt Business Overview

12.11.3 Mallinckrodt Revenue in Urological Medications Business (2021-2026)

12.11.4 Mallinckrodt Urological Medications Product Portfolio

12.11.5 Mallinckrodt Recent Developments

12.12 Endo International

12.12.1 Endo International Company Information

12.12.2 Endo International Business Overview

12.12.3 Endo International Revenue in Urological Medications Business (2021-2026)

12.12.4 Endo International Urological Medications Product Portfolio

12.12.5 Endo International Recent Developments

12.13 Bayer HealthCare Pharmaceuticals

12.13.1 Bayer HealthCare Pharmaceuticals Company Information

12.13.2 Bayer HealthCare Pharmaceuticals Business Overview

12.13.3 Bayer HealthCare Pharmaceuticals Revenue in Urological Medications Business (2021-2026)

12.13.4 Bayer HealthCare Pharmaceuticals Urological Medications Product Portfolio

12.13.5 Bayer HealthCare Pharmaceuticals Recent Developments

12.14 Astellas Pharma

12.14.1 Astellas Pharma Company Information

12.14.2 Astellas Pharma Business Overview

12.14.3 Astellas Pharma Revenue in Urological Medications Business (2021-2026)

12.14.4 Astellas Pharma Urological Medications Product Portfolio

12.14.5 Astellas Pharma Recent Developments

12.15 ADVANZ PHARMA

12.15.1 ADVANZ PHARMA Company Information

12.15.2 ADVANZ PHARMA Business Overview

12.15.3 ADVANZ PHARMA Revenue in Urological Medications Business (2021-2026)

12.15.4 ADVANZ PHARMA Urological Medications Product Portfolio

12.15.5 ADVANZ PHARMA Recent Developments

13 Report Conclusion

14 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Urological Medications Market Size by Type (2021-2026) & (US\$ Million)
- Table 6: Global Urological Medications Revenue Market Share by Type (2021-2026)
- Table 7: Global Urological Medications Forecasted Market Size by Type (2027-2032) & (US\$ Million)
- Table 8: Global Urological Medications Revenue Market Share by Type (2027-2032)
- Table 9: Global Urological Medications Market Size by Application (2021-2026) & (US\$ Million)
- Table 10: Global Urological Medications Revenue Market Share by Application (2021-2026)
- Table 11: Global Urological Medications Forecasted Market Size by Application (2027-2032) & (US\$ Million)
- Table 12: Global Urological Medications Revenue Market Share by Application (2027-2032)
- Table 13: Global Urological Medications Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 14: Global Urological Medications Market Size by Region (2021-2026) & (US\$ Million)
- Table 15: Global Urological Medications Market Share by Region (2021-2026)
- Table 16: Global Urological Medications Forecasted Market Size by Region (2027-2032) & (US\$ Million)
- Table 17: Global Urological Medications Market Share by Region (2027-2032)
- Table 18: Urological Medications Industry Trends
- Table 19: Urological Medications Industry Drivers
- Table 20: Urological Medications Industry Opportunities and Challenges
- Table 21: Urological Medications Market Restraints
- Table 22: Global Top Urological Medications Players by Revenue (US\$ Million) & (2021-2026)
- Table 23: Global Urological Medications Revenue Market Share by Players (2021-2026)
- Table 24: Global Urological Medications Industry Players Ranking, 2024 VS 2025 VS 2026
- Table 25: Global Key Players of Urological Medications, Headquarters and Area Served
- Table 26: Global Urological Medications Players, Product Type & Application
- Table 27: Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28: Global Urological Medications by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 29: Players Mergers & Acquisitions, Expansion Plans
- Table 30: North America Urological Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 31: North America Urological Medications Market Size by Country (2021-2026) & (US\$ Million)
- Table 32: North America Urological Medications Market Size by Country (2027-2032) & (US\$ Million)
- Table 33: Europe Urological Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 34: Europe Urological Medications Market Size by Country (2021-2026) & (US\$ Million)
- Table 35: Europe Urological Medications Market Size by Country (2027-2032) & (US\$ Million)
- Table 36: Asia Pacific Urological Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 37: Asia Pacific Urological Medications Market Size by Region (2021-2026) & (US\$ Million)
- Table 38: Asia Pacific Urological Medications Market Size by Country (2027-2032) & (US\$ Million)
- Table 39: South America Urological Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 40: South America Urological Medications Market Size by Country (2021-2026) & (US\$ Million)
- Table 41: South America Urological Medications Market Size by Country (2027-2032) & (US\$ Million)
- Table 42: Middle East & Africa Urological Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 43: Middle East & Africa Urological Medications Market Size by Country (2021-2026) & (US\$ Million)
- Table 44: Middle East & Africa Urological Medications Market Size by Country (2027-2032) & (US\$ Million)
- Table 45: Abbott Company Information
- Table 46: Abbott Business Overview
- Table 47: Abbott Revenue in Urological Medications Business (2021-2026) & (US\$ Million)
- Table 48: Abbott Urological Medications Product Portfolio
- Table 49: Abbott Recent Developments
- Table 50: Novartis Company Information
- Table 51: Novartis Business Overview
- Table 52: Novartis Revenue in Urological Medications Business (2021-2026) & (US\$ Million)
- Table 53: Novartis Urological Medications Product Portfolio
- Table 54: Novartis Recent Developments
- Table 55: Merck Company Information

- Table 56: Merck Business Overview
- Table 57: Merck Revenue in Urological Medications Business (2021-2026) & (US\$ Million)
- Table 58: Merck Urological Medications Product Portfolio
- Table 59: Merck Recent Developments
- Table 60: Lilly Company Information
- Table 61: Lilly Business Overview
- Table 62: Lilly Revenue in Urological Medications Business (2021-2026) & (US\$ Million)
- Table 63: Lilly Urological Medications Product Portfolio
- Table 64: Lilly Recent Developments
- Table 65: Pfizer Company Information
- Table 66: Pfizer Business Overview
- Table 67: Pfizer Revenue in Urological Medications Business (2021-2026) & (US\$ Million)
- Table 68: Pfizer Urological Medications Product Portfolio
- Table 69: Pfizer Recent Developments
- Table 70: GlaxoSmithKline Company Information
- Table 71: GlaxoSmithKline Business Overview
- Table 72: GlaxoSmithKline Revenue in Urological Medications Business (2021-2026) & (US\$ Million)
- Table 73: GlaxoSmithKline Urological Medications Product Portfolio
- Table 74: GlaxoSmithKline Recent Developments
- Table 75: AbbVie Company Information
- Table 76: AbbVie Business Overview
- Table 77: AbbVie Revenue in Urological Medications Business (2021-2026) & (US\$ Million)
- Table 78: AbbVie Urological Medications Product Portfolio
- Table 79: AbbVie Recent Developments
- Table 80: Viatrix Company Information
- Table 81: Viatrix Business Overview
- Table 82: Viatrix Revenue in Urological Medications Business (2021-2026) & (US\$ Million)
- Table 83: Viatrix Urological Medications Product Portfolio
- Table 84: Viatrix Recent Developments
- Table 85: Sanofi-aventis U.S. LLC Company Information
- Table 86: Sanofi-aventis U.S. LLC Business Overview
- Table 87: Sanofi-aventis U.S. LLC Revenue in Urological Medications Business (2021-2026) & (US\$ Million)
- Table 88: Sanofi-aventis U.S. LLC Urological Medications Product Portfolio
- Table 89: Sanofi-aventis U.S. LLC Recent Developments
- Table 90: Piramal Pharma Solutions Company Information
- Table 91: Piramal Pharma Solutions Business Overview
- Table 92: Piramal Pharma Solutions Revenue in Urological Medications Business (2021-2026) & (US\$ Million)
- Table 93: Piramal Pharma Solutions Urological Medications Product Portfolio
- Table 94: Piramal Pharma Solutions Recent Developments
- Table 95: Mallinckrodt Company Information
- Table 96: Mallinckrodt Business Overview
- Table 97: Mallinckrodt Revenue in Urological Medications Business (2021-2026) & (US\$ Million)
- Table 98: Mallinckrodt Urological Medications Product Portfolio
- Table 99: Mallinckrodt Recent Developments
- Table 100: Endo International Company Information
- Table 101: Endo International Business Overview
- Table 102: Endo International Revenue in Urological Medications Business (2021-2026) & (US\$ Million)
- Table 103: Endo International Urological Medications Product Portfolio
- Table 104: Endo International Recent Developments
- Table 105: Bayer HealthCare Pharmaceuticals Company Information
- Table 106: Bayer HealthCare Pharmaceuticals Business Overview
- Table 107: Bayer HealthCare Pharmaceuticals Revenue in Urological Medications Business (2021-2026) & (US\$ Million)
- Table 108: Bayer HealthCare Pharmaceuticals Urological Medications Product Portfolio
- Table 109: Bayer HealthCare Pharmaceuticals Recent Developments
- Table 110: Astellas Pharma Company Information
- Table 111: Astellas Pharma Business Overview
- Table 112: Astellas Pharma Revenue in Urological Medications Business (2021-2026) & (US\$ Million)
- Table 113: Astellas Pharma Urological Medications Product Portfolio
- Table 114: Astellas Pharma Recent Developments
- Table 115: ADVANZ PHARMA Company Information
- Table 116: ADVANZ PHARMA Business Overview
- Table 117: ADVANZ PHARMA Revenue in Urological Medications Business (2021-2026) & (US\$ Million)
- Table 118: ADVANZ PHARMA Urological Medications Product Portfolio
- Table 119: ADVANZ PHARMA Recent Developments

- Table 120: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Urological Medications Product Image
- Figure 5: Global Urological Medications Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 6: Global Urological Medications Market Share by Type: 2025 VS 2032
- Figure 7: Anticholinergics Product
- Figure 8: Alpha Blockers Product
- Figure 9: 5-Alpha Inhibitors Product
- Figure 10: Others Product
- Figure 11: Global Urological Medications Market Size by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 12: Global Urological Medications Market Share by Application: 2025 VS 2032
- Figure 13: OAB Product
- Figure 14: ED Product
- Figure 15: Prostate Cancer Product
- Figure 16: BPH Product
- Figure 17: SUI Product
- Figure 18: Others Product
- Figure 19: Global Urological Medications Market Size (US\$ Million), Year-over-Year: 2021-2032
- Figure 20: Global Urological Medications Market Size, (US\$ Million), 2021 VS 2025 VS 2032
- Figure 21: Global Urological Medications Market Share by Region: 2025 VS 2032
- Figure 22: Global Urological Medications Market Share by Players in 2025
- Figure 23: Global Urological Medications Manufacturers Established Date
- Figure 24: Global Top 5 and 10 Urological Medications Players Market Share by Revenue in 2025
- Figure 25: Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 26: North America Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 27: North America Urological Medications Market Share by Country (2021-2032)
- Figure 28: United States Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 29: Canada Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 30: Mexico Urological Medications Market Share by Country (2021-2032)
- Figure 31: Europe Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 32: Europe Urological Medications Market Share by Country (2021-2032)
- Figure 33: Germany Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 34: France Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 35: U.K. Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 36: Italy Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 37: Spain Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 38: Russia Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 39: Netherlands Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 40: Nordic Countries Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 41: Asia-Pacific Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 42: Asia-Pacific Urological Medications Market Share by Country (2021-2032)
- Figure 43: China Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 44: Japan Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 45: South Korea Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 46: India Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 47: India Urological Medications Market Share by Country (2021-2032)
- Figure 48: Australia Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 49: China Taiwan Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 50: Southeast Asia Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 51: South America Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 52: South America Urological Medications Market Share by Country (2021-2032)
- Figure 53: Brazil Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 54: Argentina Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 55: Chile Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 56: Colombia Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 57: Peru Urological Medications Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 58: Abbott Revenue Growth Rate in Urological Medications Business (2021-2026)
- Figure 59: Novartis Revenue Growth Rate in Urological Medications Business (2021-2026)
- Figure 60: Merck Revenue Growth Rate in Urological Medications Business (2021-2026)

- Figure 61: Lilly Revenue Growth Rate in Urological Medications Business (2021-2026)
- Figure 62: Pfizer Revenue Growth Rate in Urological Medications Business (2021-2026)
- Figure 63: GlaxoSmithKline Revenue Growth Rate in Urological Medications Business (2021-2026)
- Figure 64: AbbVie Revenue Growth Rate in Urological Medications Business (2021-2026)
- Figure 65: Viartis Revenue Growth Rate in Urological Medications Business (2021-2026)
- Figure 66: Sanofi-aventis U.S. LLC Revenue Growth Rate in Urological Medications Business (2021-2026)
- Figure 67: Piramal Pharma Solutions Revenue Growth Rate in Urological Medications Business (2021-2026)
- Figure 68: Mallinckrodt Revenue Growth Rate in Urological Medications Business (2021-2026)
- Figure 69: Endo International Revenue Growth Rate in Urological Medications Business (2021-2026)
- Figure 70: Bayer HealthCare Pharmaceuticals Revenue Growth Rate in Urological Medications Business (2021-2026)
- Figure 71: Astellas Pharma Revenue Growth Rate in Urological Medications Business (2021-2026)
- Figure 72: ADVANZ PHARMA Revenue Growth Rate in Urological Medications Business (2021-2026)